Close
Achema middle east
swop processing & packaging

FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Korean Biopharma Market to Double Biopharma Exports By 2030

The South Korean government has gone on to hold...

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

The US FDA granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Eli Lilly and Sandia National Laboratories.

The Lilly SARS-CoV-2 Assay is designed to detect the virus’ nucleocapsid gene in nasopharyngeal, oropharyngeal, anterior nasal, and midturbinate swabs, as well as nasal aspirates, nasal washes, and bronchoalveolar lavage fluid. Nucleic acid is purified using Qiagen’s QIAcube HT, and the test runs on Thermo Fisher Scientific’s Applied Biosystems QuantStudio 7 Flex, Applied Biosystems QuantStudio Dx, or Applied Biosystems QuantStudio 12K Flex RT-PCR systems.

The test may be performed only by Indianapolis-based Eli Lilly, according to the FDA.

Sandia’s SNL-NM 2019 nCoV Real-Time RT-PCR Diagnostic assay is designed to detect the SARS-CoV-2 nucleocapsid gene in upper respiratory and bronchoalveolar lavage specimens. RNA is isolated using Zymo Research’s Quick-RNA Viral Kit, and the test runs on Thermo Fisher’s Applied Biosystems 7500 or Applied Biosystems Quant Studio 5 systems or on Bio-Rad’s CFX Connect or CFX96 instruments. Use of the test is limited to Livermore, California-based Sandia, the FDA said.

Latest stories

Related stories

Korean Biopharma Market to Double Biopharma Exports By 2030

The South Korean government has gone on to hold...

Matica Bio Gets a U.S. Biotech Commercial Manufacturing Deal

Matica Biotechnology, Inc., which happens to be a leading...

The Latest Breakthroughs in Dental Treatments

Dental care has moved well beyond fillings and routine...

How Can Digital Tools Improve Medication Adherence in Patients?

Medication adherence has long been one of healthcare’s toughest...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »